These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36896312)

  • 21. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.
    Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA
    Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future.
    Barhli A; Cros J; Bartholin L; Neuzillet C
    Dig Liver Dis; 2018 Oct; 50(10):979-990. PubMed ID: 30205952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.
    Principe DR; Underwood PW; Korc M; Trevino JG; Munshi HG; Rana A
    Front Oncol; 2021; 11():688377. PubMed ID: 34336673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
    Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
    Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
    Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.
    Sielaff CM; Mousa SA
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1205-1217. PubMed ID: 29721665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling.
    Ettrich TJ; Sturm N; Güthle M; Hüttner FJ; Perkhofer L
    Visc Med; 2022 Feb; 38(1):20-29. PubMed ID: 35295894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study.
    Caputo D; Cartillone M; Cascone C; Pozzi D; Digiacomo L; Palchetti S; Caracciolo G; Coppola R
    Pancreatology; 2018 Sep; 18(6):661-665. PubMed ID: 29914752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
    Zhang Y; Huang ZX; Song B
    World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and Future Therapies for Pancreatic Ductal Adenocarcinoma.
    Sally Á; McGowan R; Finn K; Moran BM
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights.
    Kole C; Charalampakis N; Tsakatikas S; Frountzas M; Apostolou K; Schizas D
    Cancer Manag Res; 2022; 14():1043-1061. PubMed ID: 35300059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
    Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
    Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.